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Abstract
In addition to the devastating symptoms of dementia, Alzheimer’s disease (AD) is characterized by accumulation of the
processing products of the amyloid-β (Aβ) peptide precursor protein (APP). APP’s non-pathogenic functions include
regulating intracellular iron (Fe) homeostasis. MicroRNAs are small (~ 20 nucleotides) RNA species that instill specificity to
the RNA-induced silencing complex (RISC). In most cases, RISC inhibits mRNA translation through the 3′-untranslated
region (UTR) sequence. By contrast, we report a novel activity of miR-346: specifically, that it targets the APP mRNA 5′-
UTR to upregulate APP translation and Aβ production. This upregulation is reduced but not eliminated by knockdown of
argonaute 2. The target site for miR-346 overlaps with active sites for an iron-responsive element (IRE) and an interleukin-1
(IL-1) acute box element. IREs interact with iron response protein1 (IRP1), an iron-dependent translational repressor. In
primary human brain cultures, miR-346 activity required chelation of Fe. In addition, miR-346 levels are altered in late-
Braak stage AD. Thus, miR-346 plays a role in upregulation of APP in the CNS and participates in maintaining APP
regulation of Fe, which is disrupted in late stages of AD. Further work will be necessary to integrate other metals, and IL-1
into the Fe-miR-346 activity network. We, thus, propose a “FeAR” (Fe, APP, RNA) nexus in the APP 5′-UTR that includes
an overlapping miR-346-binding site and the APP IRE. When a “healthy FeAR” exists, activities of miR-346 and IRP/Fe
interact to maintain APP homeostasis. Disruption of an element that targets the FeAR nexus would lead to pathogenic
disruption of APP translation and protein production.
Introduction
Alzheimer’s disease (AD) is a neurodegenerative disorder
most typical of old age (65+). The disease is characterized
by extracellular neuritic plaques that consist mostly of
amyloid-β (Aβ) peptide. Neurofibrillary tangles (NFT) of
hyperphosphorylated tau occur within neurons, whereas
gliosis, neuroinflammation, and synaptic loss are also evi-
dent in the hippocampi and brain cortices of affected indi-
viduals [1, 2]. Although autosomally dominant inherited
(familial) forms of AD exist, they constitute no more than
5% of AD cases [2]. AD (familial and sporadic) is influ-
enced by multiple genetic and environmental factors, and
these factors are considered particularly influential in
sporadic AD [3, 4], which requires the study of multiple
molecular targets, mechanisms, pathways, and therapeutic
strategies [5–8]. Significant evidence supports an Aβ-centric
view of AD, e.g., carriers of a protective Aβ precursor
protein (APP) polymorphism, APP A673T (Icelandic) [9],
have reduced: incidence of AD, of Aβ levels throughout
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their lives, and of Aβ aggregation. The Aβ peptide is
cleaved from the APP by β-secretase (or BACE1) and γ-
secretase complex [10].
APP has non-pathogenic functions. Although Aβ accu-
mulation is a typical pathological feature of AD, the insti-
gating disease mechanism is still very poorly understood.
How could disruption of APP in the normal brain contribute
to neuropathogenesis? A vital physiological role for APP is
metal regulation, including ferrohomeostasis [11, 12]. Fur-
ther, Fe stimulates production of APP protein [13–15]. This
is particularly relevant given ample evidence of Fe dysho-
meostasis in AD [13, 16]. Notably, non-amyloidogenic
processing of APP is enhanced by increasing Fe levels, but
only up to a threshold, at which point, additional Fe inhibits
non-amyloidogenic APP processing [17]. Monomeric Aβ
reduces oxidative stress brought about by metals, in parti-
cular, monomeric Aβ inhibits reduction of Fe(III) and pre-
vents lipid peroxidation induced by Fe(II) [18]. Current
work in the regulation of APP production by Fe has con-
centrated on an iron-responsive element (IRE) in the APP
mRNA 5′-UTR [14, 15, 19, 20].
We have previously shown the regulatory effects of
several microRNA (miRNA) species on AD-associated
gene products, including miR-101 and miR-153, which act
Fig. 1 miR-346 targets human APP 5′-UTR via a target site over-
lapping a known iron-responsive element (IRE). a Schematic of the
APP transcript indicating relative sizes of 5′-UTR, coding sequence
(CDS), and 3′-UTR. Locations of miR-101, -153, and -346 binding
sites also indicated. Binding sites for multiple other miRNAs are
omitted for clarity. b Diagram indicating miR-346 target site in the 5′-
UTR, along with a known IRE and an interleukin-1 acute box (IL-1)
that each partially overlap the miR-346 site. The IL-1 acute box
reference consensus motif is solid light blue, with the remainder of the
APP 5'-UTR fragment that responded to IL-1 treatment indicated with
a dashed line. c Sequence and predicted base-pairing of human miR-
346 with its predicted target site in the human APP 5′-UTR, including
the seed sequence interaction (red box). Sequences from multiple
mammalian species, orthologous to the predicted miR-346 target site
in the human APP 5′-UTR are shown. Red text highlights nucleotide
differences of other species' sequences when compared to human
sequence. Bold, italicized, black text in human APP 5′-UTR sequence
represents fragment of functional IRE consensus sequence. d APP 5′-
UTR reporter construct containing the APP 5′-UTR sequence inserted
upstream of a firefly luciferase CDS. Predicted target site in the 5′-
UTR reporter construct was mutated by cassette mutagenesis. Red text
highlights mutations introduced in seed sequence. e Wildtype and
target site mutant reporter luciferase expression. f WT 5′-UTR APP
reporter construct co-transfected with miR-346 along with either
200 nM negative control target protector or putative miR-346-APP 5′-
UTR target protector. *p < 0.05, n= 6. “NC TP”: negative control
target protector; 346 TP: target protector for APP 5′-UTR recognition
site of miR-346
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on the APP 3'-UTR [21, 22], and miR-339-5p on the 3'-
UTR of the BACE1 transcript [23]. In this context, miRNAs
are a unique class of small (~ 22 nt), non-coding RNA that
fine-tune gene expression. In particular, miRNAs appear in
complex interactive regulatory networks that govern both
normal function and sporadic diseases of the central nervous
system [24]. Specific miRNAs may even “co-dispose”
toward apparently disparate disorders, such as AD and
pulmonary fibrosis [25]. Mature miRNA often binds a
protein of the argonaute (AGO) family to form RNA-
induced silencing complex (RISC). The miRNA allows
RISC to recognize sites of imperfect complementarity on
target mRNA transcripts. In essence, a specific miRNA is a
“socket” that grants sequence specificity. Most known
miRNA target sites are in the 3′-untranslated regions
(UTRs) of mRNAs. RISC typically inhibits protein synth-
esis by repressing translation or destabilizing the transcript.
APP [21, 22] and BACE1 [23] are among known miRNA
targets in AD.
Our process for evaluating the impact of miRNAs for
APP expression began with non-presumptive in silico
database comparisons between 5′-UTR and 3′-UTR
sequences of genes of interest (e.g., APP and BACE1) vs
known miRNA seed sequences [26]. We not only predicted
but biologically tested multiple potential miRNA regulators
of APP [21–23]; miR-346 was found among the database
predictions.
Interestingly, miR-346 may have broad neuropsychiatric
influence. An analysis of predicted miRNA:mRNA inter-
actions for schizophrenia-associated gene products revealed
that miR-346 contains a higher rate of predicted interactions
than expected by chance [27]. Of greater interest, miR-346
expression decreased in the brains of schizophrenic and
bipolar patients relative to control patients [27]. Para-
doxically, elevated miR-346 has also been reported in the
blood of schizophrenia patients, with strong diagnostic
utility (AUC 0.713; specificity 90.2%) [28]. The coding
sequence for pri-miR-346 is hosted in intron 2 of a known
schizophrenia-susceptibility gene, glutamate receptor delta
1 subunit (GRID1) [27]. However, expression of miR-346
appears to be driven independently from GRID1 expression,
based on miR-346-GRID1 correlation analyses [27, 28].
Although no specific association (risk or protective) has
been identified near the GRID1 locus for AD, it may be
noteworthy that genetic risks for schizophrenia and AD may
be at least somewhat inversely related [30], although spe-
cific genes highlighted in the reference are not reported to
be regulated by miR-346.
We now demonstrate herein unique characteristics for
miR-346. First, unlike most miRNAs, miR-346 interacts
with the APP 5′-UTR (Fig. 1a). Second, miR-346 upregu-
lates APP mRNA translation. Third, the specific effect of
miR-346 on APP expression is enhanced by intracellular
iron chelation with deferroxamine in human primary neu-
ronal enriched cultures. Finally, this target site for miR-346
overlaps with active sites for iron response protein 1 (IRP1)
and an interleukin-1 (IL-1) acute box (Fig. 1b). In addition,
this segment of the APP 5'-UTR may respond to other
cytokines, including transforming growth factor (TGF)α
and TGFβ [89].
We chose to do the bulk of our work in human primary
neuronal enriched cultures because our characterization
revealed that they showed critical similarities to active
neurons in an accompanying matrix of cells that render it
particularly valuable for neurological research. These cul-
tures were viable in vitro up to at least 40 days in culture.
Cell morphology included neuronal morphology, with a
network of processes [31]. Immunocytochemistry revealed
the presence of pan-neuronal, astrocytic (GFAP) [31], and
neuroprogenitor (nestin-1) (Supplemental Fig. 1) markers,
distinct to individual cells. Protein characterization of cul-
tures showed the presence of neuron-specific enolase,
GFAP, and synaptosome associated protein-25 [31]. The
cultures contain serotonergic, dopaminergic, and
GABAergic neuronal cells, although the preponderance of
each changes over culture age [31]. Of particular note, these
cultures contained cells that were not only morphologically
and biochemically neuronal, but cultures also had neuronal
functional response, as measured by KCl depolarization
[31]. Over time, mature neuronal population within the
cultures increased [31]. Finally, the cultures were practical
for transfection studies [31]. As such, we deemed them an
appropriate model for the present work of exploring neu-
ronal effects of miR-346 upon the APP 5′-UTR.
Based on our present work, we propose a “FeAR” (Fe,
APP, RNA) nexus in the APP 5′-UTR that comprises an
overlapping miR-346-binding site and the APP IRE. When
a “healthy FeAR” exists, activities of miR-346 and IRP/Fe
interact to maintain APP homeostasis. Disruption of an
element that targets the FeAR nexus would lead to patho-
genic disruption of APP translation and protein production.
Materials and methods
Prediction of miR-346 binding site in APP 5′-UTR
We scanned the APP 5′-UTR with the miRanda utility on
the RegRNA web server [26] to determine potential miRNA
recognition sequences.
Alignment of mammalian APP 5′-UTR sequences
Sequences corresponding to the APP 5′-UTR from 28 spe-
cies were downloaded from GenBank and aligned with
WEBPRank [32]. Total information content of alignments
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with two major gaps was calculated as
P
2þPtb¼a fb;i  log2 fb;i
 
[33], where fb,i is the relative
frequency of a nucleotide (A, C, G, T) b at position i. SE for
information was estimated by
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
P
1
ln 2 32n
 2
q
, where n is
the number of sequences at a position without a gap.
Generation of mutant miR-346 site APP 5′-UTR
reporter clone
The pGAL reporter construct was used to study regulatory
effects on the APP 5′-UTR [13]. Mutagenesis at a predicted
miR-346 target site in this 5′-UTR proved refractory to
standard site-directed mutagenesis procedures. Therefore,
cassette mutagenesis was employed instead. In this form of
mutagenesis, the region of plasmid DNA to be mutated was
excised by restriction digest. A mutagenized version of this
cassette was synthesized, annealed, digested, and ligated
into the linearized vector. The oligonucletoides to replace
the miR-346 target site in the APP 5′-UTR were obtained
from Integrated DNA Technologies (Coralville, IA). We
double digested pGAL with HindIII and NcoI. The digested
plasmid was resolved by agarose gel electrophoresis, bands
containing linearized plasmid were excised and purified
with QIAQuick Gel Extraction kit. Mutant oligonucleotides
were designed so that, once annealed, the 5′ and 3′ ends
would form sticky ends to match HindIII and NcoI sites in
the linearized pGAL. Oligonucleotides were annealed and
directly ligated into linearized pGAL by combining
annealed cassette, linearized pGAL, T4 ligase buffer, and
T4 ligase in a 20 µL final volume and incubating at room
temperature for 2 h. Approximately, 1 µL of ligase reaction
mix was then transformed into Z-competent Escherichia
coli and plated overnight. True clones were confirmed by
direct sequencing of plasmid DNA. Mutagenic oligonu-
cleotides were miR-346mut 5′:
5′-AGCTTAGTTTCCTCGGCAGCGGTAGGCGAGA
GCACGCGGAGGAGCGTGCGCGGGGGCCCCGGGA
GACGGCGGCGGTGGCGGCGCGAATGAGGCAAGG
ACGCGGCGGATCCCACTCGCACAGCAGCGCACTC
GGTGCCCCGCGCAGGGTCGCGC-3 and miR-346mut
3′: 5′-CATGGCGCGACCCTGCGCGGGGCACCGAGTG
CGCTGCTGTGCGAGTGGGATCCGCCGCGTCCTTGC
CTCATTCGCGCCGCCACCGCCGCCGTCTCCCGGGG
CCCCCGCGCACGCTCCTCCGCGTGCTCTCGCCTAC
CGCTGCCGAGGAAACTA-3′. Boldface indicates speci-
fically mutated nucleotides. Sequencing oligonucleotides
was 5′-CTGCTGTGCGAGTGGGAT-3′.
Cell culturing
HeLa (human cervical adenocarcinoma), U373 (human
brain astrocytoma), SK-N-SH (human bone marrow
neuroblastoma), 293T (human kidney epithelial), and NT2
(NTera2/D1, human lung carcinoma) cells were obtained
from American Tissue Type Culture Collection (ATCC,
Manassas, VA). Cells were grown on tissue-culture treated
plasticware (Corning, Tewksbury, MA) and maintained at
37 °C in a humidified incubator containing 5% CO2.
HeLa, 293T, U373, and SK-N-SH were grown in minimum
essential media (MEM) (Cellgro, Manassas, VA) supple-
mented with 10% fetal bovine serum (FBS) (Atlanta Bio-
logicals, Lawrenceville, GA) and 1% penicillin–
streptomycin–amphotericin solution (Cellgro). NT2 cells
were maintained in Dulbecco’s modified eagle’s media
(Cellgro) supplemented with 10% FBS and 1% antibiotic
cocktail. Cells were routinely assessed for mycoplasma
contamination by use of a commercially available assay.
Short tandem repeat profiling was not routinely performed
over the course of these experiments.
We cultured human primary neuronal enriched ("human
primary") cultures according to procedures we developed
and reported [31]. Primary cultures were prepared from the
brain parenchyma of aborted fetuses (80–100 days gesta-
tional age). The tissues were obtained from the Birth
Defects Research Laboratory (BDRL) at the University of
Washington with approval from the Indiana University
Institutional Review Board (IRB). Fetal brain materials (10–
20 g) were shipped overnight in chilled Hibernate-E med-
ium (Invitrogen, Grand Island, NY) supplemented with 1 ×
B27 serum-free supplement (Invitrogen), 0.5 mM Gluta-
MAX (Invitrogen), and antibiotic–antimycotic solution
(Cellgro).
Tissues were digested in 0.05% trypsin/0.53 mM ethy-
lenediaminetetraacetic (EDTA) acid solution and incubated
in a shaking water bath (150 rpm) at 37 °C for 15 min.
Trypsin-digested tissues were transferred to Hibernate-E
and triturated several times with a siliconized, fire-polished
pipette followed by centrifugation at 400×g, 15 min. The
cell pellet was resuspended in Hibernate-E and triturated
once more followed by centrifugation. The pellet was
resuspended in culture medium (see below) and cells
counted by Trypan blue exclusion.
Cells were plated at a density of 2–4 × 105 cells per well
on poly-D-lysine (Sigma-Aldrich, St Louis, MO) coated 24-
well plates in Neurobasal medium (Invitrogen), supple-
mented with 1 × B27, 0.5 mM GlutaMAX, 5 ng/ml Basic
fibroblast growth factor (bFGF, Invitrogen) and antibiotic–
antimycotic cocktail. Half media changes were performed
every fourth day of culture. Cell culture health was assessed
by Cell-Titer Glo (CTG) luminescent cell viability assay
(Promega, Madison WI), which measures ATP generation.
For those experiments wherein cells were treated with
deferroxamine mesylate (DFO, Sigma-Aldrich, St. Louis
MO), the appropriate volume of DFO was prepared from a
5mg/ml stock solution in phosphate-buffered saline (PBS)
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and added to human primary cell culture plates approximately
one hour prior to transfection or HeLa cells were treated with
DFO added to cultures for 72 h before harvesting.
Transfection of DNA vectors or RNA
oligonucleotides into cell lines and primary cultures
We transfected several commercially obtained miRNA and
siRNA molecules (Supplemental Table 1). During all
transfections, antibiotics were omitted from cell culture
media. Lipofection was used for all transfections, either with
Transfectin (Bio-Rad, Hercules, CA) or Lipofectamine
RNAiMAX (Invitrogen). In all experiments where negative
control RNA oligonucleotides (i.e., miRNA mimics, miRNA
inhibitors, target protectors) were transfected, we used uni-
versal negative controls (Supplemental Table 1). These
controls are not scrambled sequences and therefore do not
necessarily have base composition identical to the experi-
mental oligonucleotides for which they serve as controls.
In those experiments that used the pGAL reporter construct
with luciferase-expressing cassette or mutated pGAL, we
transfected into HeLa cells. HeLa cells (5 × 104 cells per well)
were cultured in white-walled 96-well plates, each well con-
taining 100 µl of serum-supplemented media/well, and trans-
fected with 150–300 ng of reporter constructs using
Transfectin. Transfection complexes were prepared by incu-
bating DNA in 20 µl per well of serum-free medium, with
0.75 µl Transfectin per well for 15–20min. Mixture was
directly added to cells on-plate in serum-containing media.
Luciferase assays were performed 48 h after transfection.
HeLa cells were co-transfected with reporter constructs
and miRIDIAN miRNA mimics (Dharmacon, Lafayette,
CO) by incubating HeLa cells cultured in 96-well plates
(5 × 104 cells per well) with 150 ng reporter DNA and 40
nM miRNA mimic using 0.2 µl Transfectin per well.
Transfection complexes were prepared as described herein.
We did single transfections of Silencer Select siRNA
(Applied Biosystems, Carlsbad, CA), miRNA mimics or
miRNA target protectors (Qiagen, Valencia, CA) into HeLa
or U373 cells using RNAiMAX reagent (human primary
cultures discussed below). For most experiments, HeLa
cells (1.35 × 105 cells per well) and U373 cells (7.5 × 104
cells per well) were cultured onto 24-well plates and
reverse-transfected [34]. In reverse transfections, transfec-
tion complexes are added to cultures at the same time as
cells are plated. Cells are initially transfected in suspension
until they settle and adhere onto the plate. HeLa cells were
transfected with either 20 nM siRNA, 50 nM miRNA
mimic, or 100–1000 nM miRNA target protector (TP) using
0.5 µl RNAiMAX per well. Transfection complexes were
prepared in 50 µl Opti-MEM serum-free media (Invitrogen)
with 10–15 min incubation periods prior to mixing with cell
suspensions. U373 cells were similarly transfected with 75
nM miRNA mimics using 3.5 µl RNAiMAX per well. In
several cases, miRNA mimics were co-transfected into
HeLa cells with siRNA or miRNA target protectors. In
these cases, RNAiMAX levels were boosted to 1 µl per well
to account for the increase in nucleic acid content.
Multiple batches of human primary cultures were trans-
fected at days in vitro (DIV) 17 in 24-well plates. Cultures
were transfected with 20 nM siRNA, 150 nM miRNA
mimics, and 1000 nM LNA miRNA inhibitors (Exiqon,
Woburn, MA), using 1.25 µl RNAiMAX per well. bFGF
supplementation was omitted from media during transfec-
tions. In one series of experiments, human primary cultures
were transfected with miRNA mimics in the presence of
150 µM DFO. The appropriate volume of DFO was pre-
pared from a 5 mg/ml stock solution in PBS and added to
cell culture plates ~1 h prior to transfection.
In all experiments, employing transfection of small RNA
oligonucleotides, transfection efficiency was assessed qua-
litatively by including a siRNA transfection (20 nM) against
the gene product of interest. These siRNA were validated in
HeLa cells as capable of reducing APP or BACE1 protein
and mRNA expression to < 5% of mock or negative control
siRNA transfections.
Human brain samples
Two independent cohorts of brain specimens were utilized
in this study. The first set of specimens was provided by Dr.
Peter T. Nelson from the University of Kentucky Alzheimer
Disease Brain Bank. These specimens were isolated from
BA9 of the frontal cortex and consisted of both control (n=
5) and AD (n= 15) specimens. These specimens were age-
matched with a mean age for control specimens of 84.0 ±
2.2 years and 80.8 ± 1.7 years for AD specimens. All AD
specimens had advanced AD neuropathology (Braak stage
VI and CERAD (Consortium to Establish a Registry for
Alzheimer’s Disease) neuropsychological battery score C).
CERAD score combines quantification of neuritic plaque in
specific brain regions with presence or absence of dementia.
Importantly, all specimens were collected following a short
PMI (range 1.75–8 h). Finally, the AD component of this
cohort consisted of three subgroups defined by history of
treatment with AD medications: no history of AD medica-
tion (No Rx; n= 5), history of treatment with rivastigmine
but not memantine (n= 5), and history of treatment with
memantine but not rivastigmine (n= 5).
The second set of specimens originated from the Harvard
Tissue Resource Center and was provided by Dr. P.
Hemachandra Reddy. These specimens were also isolated
from BA9 of the frontal cortex and consisted of control
(n= 5) and AD (n= 15) specimens. Demographic details
were previously published [35]. The AD group was further
subdivided into three groups defined by stage of
Novel upregulation of amyloid-β precursor protein (APP) by microRNA-346 via targeting of APP mRNA. . . 349
neurofibrillary pathology: Braak stage I/II (early AD; n=
5), Braak stage III/IV (definite AD; n= 5), and Braak stage
V/VI (severe AD; n= 5). Therefore, this group consisted of
specimens spanning the stages of AD progression. Analyses
of this cohort was performed either by making comparisons
across all Braak stages or by combining control and stage I/
II and stage III–VI into two distinct groups for comparison.
The rationale for consolidating groups was to increase
power of analysis by increasing sample size. Given that
stage I/II specimens have only very mild AD pathology and
represent a very early-stage of the clinical disease, the
assumption is that control and stage I/II specimens are more
biochemically similar to one another than to either stage III/
IV or V/VI specimens.
Specimens were initially pulverized using a stainless
steel chamber, pre-chilled with liquid nitrogen. Pulverized
samples were quickly aliquoted and stored at −80 °C,
avoiding sample thawing.One aliquot of each sample was
processed for protein analysis. This frozen aliquot was
immersed in M-PER (ThermoFisher, Waltham, MA) sup-
plemented with 0.1% SDS and protease inhibitor cocktail
set III and immediately sonicated using a Sonifier Cell
Disruptor 350 (Branson, St Louis, MO) until visible clumps
were no longer apparent. Lysates were then incubated with
50 U/mL Benzonase enzyme (EMD, Billerica, MA) for
10 min at 37 °C to reduce nucleic acid content and asso-
ciated viscosity. Lysates were centrifuged down at 30,000 g
for 2 h to clear debris. Cleared supernatants were collected
and stored at −80 °C for future protein analysis. For all
brain studies, human brain specimens were analyzed in a
blinded fashion with diagnostic categories only revealed for
data analysis after performing appropriate quality control
checks and data normalization. Human brain specimens
were provided via external investigators after collection
from deceased donors and provided with no identifying
information. Therefore, research using these specimens was
deemed not to be human subject’s research as defined by
HHS and therefore exempt from institutional IRB approval.
Protein quantification, SDS-PAGE, and western
blotting
Cell lysate protein concentrations were measured by
bicinchoninic acid assay (Pierce, Rockford, IL) per the
manufacturer’s instructions. Protein concentrations were
measured with 10 µl of lysate and 200 µl of working reagent
at absorbance of 570 nM with a microplate reader (Bio-
Rad). All samples were analyzed in duplicates and absor-
bance values averaged. Concentrations were calculated by
comparison to a bovine serum albumin standard curve.
An equal amount of lysate protein (ranging from 1–5 µg)
was loaded onto Bis-Tris XT denaturing 10% SDS poly-
acrylamide gels (Bio-Rad). Proteins were resolved by
sodium dodecyl sulphate–polyacrylamide gel electrophor-
esis (SDS-PAGE) at 200 V for 1.3 h and transferred onto
polyvinylidene difluoride by electroblotting at either 30 V
for 10 h or 100 V for 1.5 h. Blots were stained with Ponceau-
S (Sigma) and visually inspected. Membranes were blocked
for 1 h in 5% non-fat milk and incubated overnight with
primary antibodies against APP (22C11, Chemicon, Bill-
erica, MA), Dicer (NeuroMAB, Davis, CA), and α-tubulin
(B-5-1-2, Sigma-Aldrich). Secondary antibody was HRP-
conjugated goat anti-mouse (Rockland Immunochemical,
Gilbertsville, PA) or HRP-conjugated rabbit anti-goat (Santa
Cruz Biotechnology, Santa Cruz, CA) for 1 h. Bands were
visualized using ECL reagent (Pierce, Rockford, IL),
detected on film and scanned for densitometric analysis.
Aβ ELISA analyses
Levels of Aβ40 were measured in the conditioned media
(CM) of human primary culture and human brain autopsy
samples using a sensitive and specific commercially available
ELISA kit (IBL America, Minneapolis, MN). Equal volume
of CM (25 µl) was loaded in a plate pre-coated with anti-
human Aβ (35–40) antibody (clone 1A10) and incubated
overnight. This kit uses HRP-conjugated anti-human Aβ (11–
28) as detection antibody. The overall assay was performed
according to the manufacturer’s instructions. In brief, CM was
added onto pre-coated plates and incubated overnight at 4 °C.
The next day plates were vigorously washed with buffer
supplied by IBL in the kit and then incubated with detection
antibody for ~1 h at 4 °C. Plates were again vigorously
washed and then incubated with chromogenic substrate tet-
ramethylbenzidine for 30mins in the dark. Chromogenic
reaction was then stopped by the addition of stop solution and
absorbance at 450 nm was read using Tecan GENios micro-
plate reader. Aβ40 values (in pg/ml of CM) were calculated
by comparison with an Aβ40 standard curve. This value was
normalized to the total lysate protein yield from each well to
control for variability attributable to differences in cell num-
ber and scaled relative to mock transfection values.
RT-qPCR analysis of mRNA and miRNA
Both mRNA and miRNA levels were quantified by
reverse transcription (RT) quantitative PCR (RT-qPCR).
All RT and qPCR steps were performed at a dedicated
PCR/RNA workbench with separate supplies to avoid
DNA or RNA contamination. For miRNA quantification,
stem-loop TaqMan assays were employed (Applied
Biosystems, Carlsbad, CA).
Briefly, total RNA (10 ng) was converted to com-
plementary DNA (cDNA) using TaqMan microRNA
Reverse Transcription kit (Applied Biosystems) by com-
bining RNA, miRNA-specific RT primer, MultiScribe
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reverse transcriptase, RNase inhibitor enzyme, dNTPs,
reaction buffer and water per the manufacturer’s protocol
and incubating reaction mix on a thermocycler at 16 °C for
30 min, 42 °C for 30 min and 85 °C for 5 min. The cDNA
was subjected to qPCR using specific TaqMan hydrolysis
probe assays (Applied Biosystems). The RT reaction mix
(cDNA) was combined with TaqMan miRNA assay and
TaqMan Universal PCR master mix (Applied Biosystems)
per the manufacturer’s protocol and analyzed on a 7300
Real-Time PCR instrument (Applied Biosystems). Each
sample was analyzed in duplicate and signals averaged.
For mRNA quantification, standard mRNA TaqMan
hydrolysis probe assays were utilized. Total RNA (10–75
ng) was converted to cDNA with the High Capacity RNA-
to-cDNA kit (Applied Biosystems) by combining total
RNA, RT enzyme mix, and RT reaction buffer per
the manufacturer’s protocol and incubating reaction mix in
a thermocycler at 37 °C for 60 min and then 95 °C for 5
min. The RT reaction mix (cDNA) was combined with
TaqMan mRNA assay and TaqMan Universal PCR master
mix as in miRNA analyses. The PCR reactions were then
analyzed on the 7300 Real-Time PCR instrument. Each
sample was analyzed in duplicate and signals averaged.
Relative quantification was performed using a modified
Δ-Cq method. Relative levels were calculated by taking the
ratio of Ex
ΔCt,x for the gene of interest to Ey
ΔCt,y for the
stable reference gene, where Ex and Ey are experimentally
determined PCR amplification efficiencies for the gene of
interest and reference gene, respectively. This is imple-
mented into the qBasePLUS software used in these studies. In
order to determine amplification efficiencies for each Taq-
Man assay, aliquots of every RNA sample in a given ana-
lysis were pooled and used to create a relative standard
curve by serial dilution. This standard curve was then
converted to cDNA and analyzed by qPCR in parallel with
unknown samples. The slope of the plot of Ct versus
standard curve dilutions was used to calculate amplification
efficiency. For miRNA relative quantification studies,
RNU48, RNU49, RNU6B, and miR-16 were used for
normalization. For mRNA relative quantification studies,
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), β2
microglobulin (B2M), β-actin, and TATA-box binding
protein (TBP) were used for normalization.
HPLC-purified synthetic oligoribonucleotide standards
were obtained commercially (Sigma and Integrated DNA
Technologies), identical in sequence to human miR-101,
miR-153, miR-346, miR-339-5p, miR-124, and miR-1.
Oligoribonucleotides were resuspended and concentrations
measured by A260 values. Standard curves with absolute
copy counts were prepared by serial dilution, converted to
cDNA, and analyzed by qPCR in parallel with unknown
samples. Copy counts per reaction were determined from
standard curve analysis. Copy counts were then presented as
copy counts/15 pg total RNA as a rough estimate of copy
counts per average human cell.
Statistical analyses
Statistical analyses were performed using Prism GraphPad,
SPSS, or R using Student’s t test and linear or generalized
linear models followed by post hoc Dunnett’s t test, Šidak-
corrected pairwise comparisons, Tukey’s Honest Significant
Difference test, or Student–Neuman–Keuls, as appropriate.
All tests used p ≤ 0.05 as the threshold for significance.
Generalized linear models were used whenever data vio-
lated the fundamental assumptions of the t test or linear
models (normality and homoscedasticity). Distribution
families and links were chosen by application of the second-
order Akaike information criterion [36]. In all cases, error
bars represent standard error of the mean. For human brain
specimen analysis, the sample size was set to be sufficient to
detect a 35% difference in means between groups. Speci-
fically, each brain specimen cohort had 5 control (non-AD)
and 15 or 20 disease patient specimens. This sample size
was sufficient at power 80% to detect a 32% difference in
means with relative standard deviation of 20% for each
group, with type I error rate (alpha) of 5%. For cell culture
experiments, sample size was determined by multiple pre-
vious works in cell culture reasonable sample sizes for our
APP and other assays [21–23].
Results
Proposed FeAR nexus is well-conserved
Sequence alignment revealed that the FeAR nexus was
well-preserved among placental mammals, particularly
primates (Fig. 1c, Supplemental Table 2). No homo-
logies were found outside the Eutheria. When expressed
in terms of information (bits), primate alignment con-
servation was 97.44 ± 1.58. Mammalian conservation
was 97.72 ± 1.02. This corresponds to a relative infor-
mation content of 91.9% ± 1.5% and 81.4% ± 0.9% vs.
100% for perfect conservation (106 bits maximum
information for primates, 140 for all species). These
calculations ignored the two large gaps in the alignment
that only had sequences for dog and/or horse. Other gaps
were accounted for by an increase in error term value for
that position owing to smaller sample size.
miR-346 activity is through the predicted target site
in the APP 5′-UTR
We used the predicted miR-346 target sequence in the APP
5′-UTR (Fig. 1c) to design a mutation (Fig. 1d) in a
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Fig. 2 miR-346 delivery dramatically upregulates APP expression in
HeLa cells. Induction of APP expression in HeLa by miR-346 delivery
is reversed when interaction with the predicted target site in the APP 5′-
UTR is blocked. a Western blot of HeLa transfected with APP siRNA,
negative control miRNA mimic, or miR-346 mimics from two inde-
pendent sources (Dharmacon or Ambion). b APP ( ~ 110–130 kDa by
the mAb22C11 probing) signal was normalized to α-tubulin protein ( ~
51 kDa) signal. APP siRNA significantly (p ≤ 0.05) depressed APP,
whereas miR-346 mimics both significantly increased it, but each was
not different from the other. Letters indicate pairwise statistical com-
parison (Tukey’s) outcomes. Samples sharing letters are not sig-
nificantly different. c CellTiter-Glo (CTG) cell viability assay of
transfected cell cultures. Transfections did not alter overall culture
viability (no omnibus or pairwise significant differences). d RT-qPCR
of miR-346 at 48 h post transfection (two technical replicates), nor-
malized to geometric mean of RNU48, RNU6B and miR16, further
scaled relative to mock-transfected levels. RQ= relative quantification;
* p < 0.05 relative to negative control-transfected cells. e APP mRNA
RT-qPCR 48 h post transfection (n= 3), normalized to geometric mean
of β-actin, B2M, GAPDH and TBP, further scaled relative to mock-
transfected levels. f APP western blot of miR-346 target protection
assay with increasing dose of the target protector and fixed amount of
miR-346. g Blots quantified by densitometric analysis and APP levels
normalized to α-tubulin levels, scaled relative to mock transfection
(n= 4). Linear analysis revealed a significant (p= 0.011) dose–
response relationship between target protector and reduction of miR-
346 activity. h CTG of target protector assay cell cultures. No effect
appeared from target protector on culture viability. i Western blot of
miR-346 treatment of U373 cell cultures. j Densitometry of APP for
U373 cultures was adjusted for α-tubulin. Although NC mimic
appeared to increase APP levels, miR-346 induced a greater increase. k
ELISA of Aβ40 in CM of U373 cells transfected with mock, NC
mimic, or miR-346. Transfection with miR-346 significantly (p < 0.05)
increased levels of Aβ40 in CM
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luciferase expression vector that contained the APP 5′-UTR
fused between the SV40 promoter and the firefly luciferase
reporter gene [37]. Co-transfection of HeLa cells with the
wildtype and mutant luciferase vectors and miR-346 mimic
resulted in significant (p ≤ 0.05) increase in luciferase signal
for wildtype APP 5′-UTR or no alteration by miR-346 for
mutated APP 5′-UTR (Fig. 1e). When we co-transfected the
wildtype APP 5′-UTR luciferase vector with miR-346 and a
TP designed to block the interaction of miR-346 at the
predicted APP 5′-UTR target site, we saw a significant
reduction of miR-346 mimic effect (Fig. 1f) vs. a negative
control TP.
miR-346 upregulates levels of APP in HeLa cells in a
consistent fashion
Transfection of HeLa cells with 50 nM of two miR-346
mimics from different commercial sources (Fig. 2a) resulted
in elevated (2–2.5-fold) levels of α-tubulin-normalized APP
(Fig. 2b). CTG (measuring overall cell culture health) was
not perturbed by this treatment (Fig. 2c). We confirmed
successful delivery of miR-346 into HeLa cells by RT-
qPCR 48 h post transfection (Fig. 2d). Normalized APP
mRNA levels in HeLa cells, assayed by RT-qPCR 48 h post
transfection, were unchanged (Fig. 2e). RT-qPCR expres-
sion levels were normalized to the geometric mean of β-
actin, B2M, GAPDH, and TBP expression levels and scaled
relative to mock-transfected levels. To confirm binding
specificity, we further transfected HeLa cells with miR-346
along with increasing concentrations of a sequence-specific
TP. Total transfected nucleic acid concentration was kept
constant by adding adjusted amounts of “negative control
target protector”. We harvested and lysed cells 72 h post
transfection, analyzed protein lysates on SDS-PAGE, and
visualized APP and β-actin by western blot on the same
membrane (Fig. 2f). We quantified by densitometric analysis
and normalized APP levels to α-tubulin levels and scaled
relative to mock transfection (n= 4).
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Fig. 3 Knockdown of AGO2 but not Dicer attenuates the upregulation
effect of miR-346 on APP expression. HeLa cells were co-transfected
with or without miR-346 mimic along with either negative control
siRNA (NCs), Dicer siRNA or AGO2 siRNA. a Model of miR-346
interaction with target APP 5′-UTR sequence. Loading onto AGO2
may provide optimal conditions. b APP levels assayed 48 h post
transfection by AGO2 or Dicer siRNA by Western blot. c AGO2/Dicer
siRNA blot (b) as quantified by densitometric analysis, arranged by
siRNA treatment. NCs: negative control. In each case, miR-346 co-
transfection significantly (p < 0.05) increased levels of α-tubulin-
adjusted APP densitometry. d Quantified AGO2/Dicer siRNA blot
outcomes, arranged by miRNA treatment. Knockdown of AGO2 or
Dicer did not significantly alter (although p < 0.10) adjusted APP
signal. However, a difference (p < 0.05) in the effect of miR-346 co-
transfection occurred when comparing AGO2 knockdown to NCs co-
transfected cells
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Endogenous cellular response to miR-346 is blocked
by protection of target site in the APP 5′-UTR
We treated HeLa cells with 15 nM miR-346 mimic and
increasing concentrations of TP. We found a significant (p=
0.011) inverse relationship between TP dose and miR-346
activity (Fig. 2g). However, CTG-based cell viability was not
perturbed (Fig. 2h). The target protection assay established
that miR-346 mimics also upregulated endogenous APP
mRNA translation. Direct blockade of the specific miR-346
recognition site within the APP mRNA reduced miR-346
mimic activity in a specific dose-dependent fashion.
miR-346 activity exists in other cell lines
We transfected miR-346 mimics into human glioblastoma
U373 cells and analyzed cell extracts on western blot (Fig. 2i).
When densitometry was adjusted by corresponding α-tubulin
signal, U373 results showed that miR-346 mimic treatment
increased APP levels (Fig. 2j). We further evaluated CM for
levels of secreted Aβ40 peptide by ELISA and found that
miR-346 treatment significantly increased Aβ40 levels in CM
of transfected U373 cells (Fig. 2k).
Activity of miR-346 in the APP 5′-UTR requires the
conventional machinery of miRNA activity
To check the role of the RISC component AGO2 on miR-
346 activity (Fig. 3a), we co-transfected HeLa cells with or
without miR-346 mimic along with either negative control
siRNA, Dicer, or AGO2 siRNA, and measured APP levels
of cell lysates 72 h post transfection by western blot
(Fig. 3b) followed by densitometry and normalization to α-
tubulin levels (Fig. 3c, d). After ANOVA testing inter-
action of siRNA ×miRNA treatments, we found a sig-
nificant interaction (p= 0.010); Šidak-adjusted pairwise
comparisons revealed that treatment with siRNA
against AGO2 reduced but did not eliminate miR-346
activity (p < 0.05).
Levels of miR-346 and APP diminish as primary
human brain cultures mature
We cultured human primary cells as described herein and
harvested cultures at 7, 10, 14, 18, 22, and 26 DIV. We
measured miR-346 levels by RT-qPCR. We determined that
miR-346 significantly decreased as cultures aged (Fig. 4a)
A. qRT-PCR of miR-346 (HFB)
Days in Vitro
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
7 10 14 18 22 26
dezila
mro
N e v ital e
R
) 1 = 81 
V I
D( 
Q
R
N
C 64 3
Ri
m
p < 0.001
ω2 = 0.651
B. α-tubulin adjusted APP
0
2
4
6
8
10
12
14
7 10 14 18 22 26
Days in Vitro
R
el
at
iv
e 
A
P
P
/α
-tu
bu
lin p < 0.001
ω2 = 0.673
-3.5
-2.5
-1.5
-0.5
0.5
1.5
2.5
3.5
Day
Marker
Day × Marker
p val.
< 0.001
0.536
0.608
ω2
0.658
0.000
0.000
7 10 14 18 22 26
Days in Vitro
re kra
M de zid radnat
S
)64 3
R i
m ro P
P
A (
C. Standardized APP and miR-346
0.0
0.5
1.0
1.5
2.0
2.5
HeLa 293T NT2 Naive SK-
N-SH
Diff SK-N-
SH
HFB
D. qRT-PCR
N
or
m
al
iz
ed
 C
N
R
Q
Fig. 4 APP and miR-346 levels in human primary culture are in accord
with each other over time. Basal levels of miR-346 appear to vary by
cell type. a RT-qPCR analysis of miR-346 levels across time in human
primary culture. RNA expression levels were normalized to the geo-
metric mean of expression levels for endogenous controls RNU6B,
RUN48 and miR-16 and then to mean level at day 18 (DIV= 1).
These were stated as “CNRQ”, the calibrated normalized relative
quantification calculated by qBasePLUS. Levels were modeled against
DIV. b Western blot bands of APP [22] were scanned and
densitometrically analyzed, and APP levels normalized to α-tubulin
and scaled relative to DIV 18 levels. Levels were modeled against
DIV. c Combined standardized model. APP and miR-346 signals were
standardized (mean subtracted and result divided by standard devia-
tion) and modeled together. Although DIV maintained significance, no
significant difference was found between APP and miR-346 standar-
dized levels. d Multiple cell lines were cultured and RNA purified as
described herein. RT-qPCR analysis of each cell line’s levels of miR-
346 was conducted
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proportionally to the square of days in culture. We measured
APP by western blot [22]. We determined that APP also
decreased proportionally to the square of DIV (Fig. 4b).
When both miR-346 and APP levels were standardized by
subtracting overall means and dividing by standard devia-
tions, the resulting trends were nearly identical (Fig. 4c).
Fig. 5 Iron chelation alters APP levels in HeLa cultures and
the upregulation effect of miR-346 on APP expression in human pri-
mary neuronal enriched culture requires iron chelation. HeLa cultures
were treated with different doses of DFO and FBS as described herein.
Human primary neuronal enriched cultures were transfected
either with negative control mimic or miR-346 mimic, in the presence
of vehicle or chelation, and proteins were analyzed on western blots.
a Western blot of APP and α-tubulin for different treatment combi-
nations of HeLa cells. “Neg Control” is NC mimic. b Densitometry
(APP/α-tubulin) of HeLa western blot. c CTG of treated HeLa. d
Mock, negative control, or miR-346 treatment of human primary
culture without chelation. e Densitometry (APP/α-tubulin) of mock/
negative/miR-346. f CTG of treated cultures. g Aβ40 levels in CM
of cultures. h Vehicle vs. DFO treatment of human primary culture. i
Densitometry (APP/α-tubulin) of APP adjusted by α-tubulin of
Vehicle vs. DFO. j CTG of treated cultures. k Aβ40 levels in CM of
treated cultures. l Co-treatment of human primary culture with DFO
and miR-346 (DFO used in all samples). m Densitometry (APP/α-
tubulin) of DFO co-treatment. n CTG of treated cultures. o Aβ40
levels of in CM of treated cultures
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Native levels of miR-346 apparently differ by cell type
RNA from human cells lines (HeLa, 293T, NT2, SK-N-
SH, and SK-N-SH treated with retinoic acid), as well as
human primary cultures (18 days in vitro) was prepared
and subjected to qRT-PCR for miR-346 levels. Results
were normalized to geometric means of corresponding
RNU6B, RNU48, and miR16 signals (Fig. 4d). We do not
report formal pairwise comparisons, as N= 2 for each cell
line, although it appears that HeLa had specifically lower
levels of miR-346 than other cell lines tested, while
human neuroblastoma (SK-N-SH) cells exhibited
increased levels of miR-346 in a differentiation specific
manner.
Iron depletion reduces expression of APP in HeLa
cultures
We treated HeLa cultures with a combination of different
concentrations of FBS (0.5%, 2%, 10%) and of DFO (0, 25,
75, 150 µM) and measured APP levels (α-tubulin adjusted)
by western blot as well as cell viability by CTG, 72 h after
treatment. Two-way modeling of FBS × DFO treatment
effects revealed no interaction. However, a significant (p ≤
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Fig. 6 Analysis of miR-346 and
Aβ levels in human brain
specimens. RT-qPCR analysis
of expression levels for miR-346
in brain specimens from AD and
control patients in both cohorts.
“AD (No Rx)” represents a
subgroup of AD patients in
cohort 1 that had no history of
treatment with cholinesterase
inhibitors or memantine. a, c, e
expression levels vs. different
Braak stages were determined
using the modified ΔCq relative
quantification method as
implemented in qBasePLUS
software. Expression levels vs.
different Braak stages were
normalized to the geometric
mean of four endogenous
controls: RNU6B, RNU48,
RNU49, and miR16. In b, d, f,
expression levels vs. different
Braak stages were quantified in
absolute terms as miRNA copy
counts per 15 pg of total RNA.
Copy counts were calculated
from standard curves prepared
from serial dilutions of miRNA
oligonucleotide standards with
known concentrations. (*p <
0.05). g Aβ40 levels in brains of
cohort 1 patients. h Aβ40 levels
in brains of cohort 2 patients
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0.05) effect was found for DFO dose vs. APP and vs. CTG.
Notably, DFO reduced APP levels by dose and increased
CTG signal (Fig. 5a–c).
Iron deficiency is necessary for miR-346 effect on
APP levels in human primary neuronal enriched
cultures
We transfected human primary cultures with miR-346
(Fig. 5d–g); treated them with DFO, 150 µM (Fig. 5h–k); or
combined miR-346 transfection and DFO treatment
(Fig. 5l–o). We quantified APP levels (adjusted by α-
tubulin) by western blot followed by densitometry. In
contrast to HeLa culture results, transfection with miR-346
in isolation did not alter APP levels. DFO treatment, alone
significantly (p ≤ 0.05) reduced adjusted APP. However,
when transfected under iron-deficient conditions (DFO
chelation), treatment with miR-346 not only reversed che-
lation effects but increased APP levels beyond untreated
culture levels. However, no treatment with DFO or miR-
346, alone or combined, significantly altered Aβ40 levels in
CM samples. We propose, therefore, that under physiolo-
gical conditions, miR-346 activity on the APP 5′-UTR
depends upon iron deficiency [38].
miR-346 levels are reduced in AD, particularly in
later Braak stages whereas AD increases
We analyzed two different cohorts of human brain tissue
specimens. Both cohorts included individuals with neuro-
pathological AD and age-matched non-AD controls. We
performed RT-qPCR analysis of miR-346 levels in brain
specimens from AD and control patients in both cohorts
(Fig. 6a–f) and Aβ peptides in cohort 1 (Fig. 6g, h). “AD
(No Rx)” represents a subgroup of patients from the AD
group that had no history of treatment with cholinesterase
inhibitors or memantine. We normalized “Relative”
expression levels to the geometric mean of four endogenous
controls: RNU6B, RNU48, RNU49, and miR-16. We cal-
culated “copies/15 pg total RNA” from standard curves
prepared from serial dilutions of miRNA oligonucleotide
standards with known concentrations. We normalized levels
of Aβ40 and Aβ42 to means of Control samples. In cohort 1
(Fig. 6a, b), both all AD and AD without medications had
significantly (p ≤ 0.05) lower levels of miR-346 than con-
trols. We found no significant differences if analyzing each
Braak stage group in cohort 2 (Fig. 6c–f) separately. When
we combined Braak stages as “Control, I/II” vs. III through
VI, we found that the reduction in miR-346 according to
Braak stage was significant. We likewise found that relative
levels of both Aβ peptides were significantly higher in
“no Rx” AD samples than controls. Aβ42 levels
were also significantly higher than controls for all AD.
Although Aβ40 levels were elevated for AD including drug-
treated patient samples, the difference was not significant
(Fig. 6g–h).
Discussion
APP plays a central role in AD etiology and progression. In
this report, we address novel features of regulation by
miRNA of APP mRNA translation. Among its many
functions, APP has metal-associated redox activity [12] and
stabilizes the plasma membrane for Fe transport (with or
without ferroxidase activity) [11, 39]. Thus, preventing
disruption of Fe metabolism is a worthwhile target of AD
research [40].
Several miRNAs, including miR-101, miR-153, and
miR-298, regulate APP mRNA translation [21, 22, 41]. To
discover further miRNA regulators of APP, we scanned the
APP 5′- and 3′-UTRs with the miRanda utility in the
RegRNA online database [26] and found a putative target
site for miR-346 in the 5′-UTR. When tested, miR-346
strongly upregulated expression of an APP 5′-UTR reporter
clone and endogenous APP protein in HeLa cells. Site
mutagenesis and TP transfections demonstrated that these
effects were mediated by specific interaction with the pre-
dicted APP 5′-UTR target site (Figs. 1–2). We also
observed an upregulatory effect in human primary cultures
but only after iron chelation. Therefore, miR-346 has “non-
canonical” (stimulative/disinhibitive) regulatory effects on
APP expression via a “non-canonical” target site in the APP
5′-UTR that likewise contains an IRE. Inhibiting the inter-
action we observed may be a viable therapeutic strategy for
potentially regulating APP expression and Aβ production in
the AD brain.
Early exploration into the upregulation of mRNA trans-
lation by miRNAs concentrated on conventional 3′-UTR
region targets. In those cases, it was determined that miR-
NAs would direct AGO and fragile-X mental retardation
syndrome-related protein (FXR1) toward AU-rich areas
(ARE) of the 3′-UTR, and many miRNA target sites (~
75%) are within AREs. Furthermore, this effect can switch
from stimulation to repression depending on whether cells
are quiescent or dividing [42]. FXR1 is a homolog of
FMRP, which is known to repress translation of APP [43].
However, more recent work has determined that stimulation
of translation by miRNA is not limited to targeting the 3′-
UTR, nor is it limited to interactions with ARE [44].
Instead, multiple pathways can operate that involve either
the 3′- or 5′-UTR and several potential protein partners,
although AGO2 is usually (but not always) present [44]. It
bears noting that the miR-346 site in the APP 5′-UTR is not
within an ARE. What is a particularly interesting contrast is
that our own work demonstrated that miR-346 stimulation
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at least partially required AGO2, while miR-346 stimulation
of RIP140 was enhanced by knockdown of AGO2 [45].
Thus, specific action of a particular miRNA on a specific
mRNA may depend closely upon local metabolic
conditions.
While most known miRNA regulatory interactions are
limited to the mRNA 3′-UTR [46], several examples exist
of effective miRNA targeting in the 5′-UTR or CDS
[45, 47], and some even target both 5′- and 3′-UTRs in a
single mRNA [48]. The vast majority of validated miRNA:
mRNA target interactions inhibit target translation. Never-
theless, several examples exist of apparent stimulation by
miRNA on target expression [44]. Most specifically, our
results for APP are similar to miR-346 regulation of
receptor-interacting protein 140 (RIP140) [45]. That is,
miR-346 stimulates translation through the RIP140 5′-UTR.
Specific differences have been reported between miRNA
activities in quiescent (G0) vs. actively dividing cells [42].
Given that we have evidence that our human primary cul-
ture contains a significant portion of mature neurons [31],
we believe that our results adequately reflect one such dif-
ference, particularly since the effects of miR-346 in HeLa
(immortalized, actively dividing cells) were not identical to
those we observed in human primary cultures.
A potentially pertinent pathway for AD is miR-346 reg-
ulation of the unfolded protein response (UPR) [29]. This
pathway activates under accumulation of unfolded proteins in
the ER. Activation of UPR results in the inhibition of global
protein production and targeted induction of gene expression
for products that increase ER protein folding capacity [49].
Expression of miR-346 increases UPR through UPR-linked
transcription factor XBP1 [29]. This leads to decreased
expression of TAP1 through interaction between miR-346
and the TAP1 3′-UTR. TAP1 is an ATP-binding cassette
transporter that translocates antigens derived from proteaso-
mal processing into the ER lumen for loading onto MHC
antigen receptors. Notably, miR-346 also decreases MHC
class I gene expression via indirect interactions, further
implicating miR-346 as an immunomodulatory miRNA.
To bring this into context with our present work, neurons
in the AD brain are often invested with NFT consisting of
aggregated hyperphosphorylated tau protein that might be
expected to induce ER stress. UPR is activated in pretangle
neurons [50]. Given that UPR is active in the AD brain and
that APP expression is elevated following UPR activation
[51], it is reasonable to speculate that miR-346 expression
may also be induced in certain cells of the AD brain and
drive APP expression in pretangle neurons. Even broader
associations between neurodegeneration and UPR likely
exist [52]. Multiple neurodegenerative diseases, including
AD, Parkinson’s disease, Huntington’s disease, and amyo-
trophic lateral sclerosis have association with activated UPR
[53]. In AD, a specific UPR-related mechanism may be
autophagy [54]. Furthermore, UPR may contribute to AD
amyloidosis. Specifically, X-box binding protein 1 (XBP1)
is a transcription factor that regulates ADAM10 [55].
ADAM10 is the primary α-secretase, which drives APP
processing away from amyloidogenic Aβ production. XBP1
is differentially spliced during UPR [56]. This specific
splicing difference likewise alters XBP1 activity on
ADAM10. In brains from AD, normal XBP1 and ADAM10
mRNA levels were below those of non-AD controls [55].
Of particular pertinence, Fe depletion reduces the ability of
cells to mount UPR against ER stress, and this is relieved by
Fe supplementation [57].
Mechanisms involved in post-transcriptional miRNA-
mediated inhibitory regulation are fairly universal and well
described [58]: AGO2 as a member of RISC recruits
GW182 to the target transcript, promoting further protein
interactions that lead to translational inhibition and tran-
script deadenylation and degradation [58, 59]. To explore
the mechanism underlying the upregulation effect of miR-
346 on APP mRNA translation, we tested involvement of
proteins implicated in canonical miRNA biogenesis (Dicer)
and function (AGO2). Upregulation of APP by miR-346
was significantly reduced when expression of AGO2 was
knocked down. AGO2 was originally discovered as a
component of a molecular complex involved in translation
initiation [60]. This function has since gone largely unex-
plored. Given the location of the miR-346 target site in the
APP 5′-UTR, near the site of ribosome assembly, one
possible explanation for the requirement of AGO2 is that it
may mediate the upregulation effect via its function in
translation initiation. Another possibility is that AGO2 may
be required to sterically inhibit interactions between inhi-
biting trans-factors and the APP 5′-UTR IRE.
The miR-346 target site in the APP 5′-UTR directly
overlaps with a known IRE and an IL-1 acute box [13, 14].
The IRE located within the APP 5′-UTR binds IRP1 but not
IRP2 [13, 14, 19]. It is possible that miR-346 activity may in
some way interact with IRP1 and/or IL-1 activity through
their co-localized target sites on the APP 5′-UTR, particularly
IRP1. In this regard, IRP1 inhibits APP translation when
bound to the 5′-UTR IRE. When iron levels are increased,
IRP1 binds free iron and dissociates from the APP mRNA
allowing translation to proceed uninhibited. When iron levels
are decreased (such as with iron chelation), free iron dis-
sociates from IRP1 allowing IRP1 to bind to the APP 5′-UTR
IRE and inhibit APP translation. IL-1 participates in Fe
homeostasis indirectly, through inflammatory cascades. In
particular, IL-1 increases recruitment of IRP1 by transient
increase of the labile Fe pool [61]. Further, IL-1 stimulates
translation of APP mRNA through its 5′-UTR [62]. In pri-
mary human primary cultures, miR-346 activity was absent
unless Fe levels were reduced by chelation with DFO.
Although it is tempting to speculate that the potent effect of
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miR-346 on APP levels in HeLa cells could be attributed to
relative Fe deficiency, we have no direct evidence of this as
we did not measure free Fe levels in media. In fact, media
supplementation with FBS would be expected to provide Fe
both in free form and bound to transferrin. Further, it is not
clear that comparing media iron levels would reflect differ-
ences in intracellular free iron levels. Therefore, the exact
mechanism whereby miR-346 regulates APP levels in HeLa
cells requires further investigation.
Nevertheless, our work allows us to build an extended
model of miR-346’s role in APP’s promotion of export of
Fe from the cytosol to the extracellular space. Aside from its
role in regulating APP expression, Fe, along with Cu and
Zn, bind to Aβ, particularly in plaque cores [63], and slows
the normal ordered progression of Aβ to higher ordered
aggregates, such as fibrils. This Fe interference promotes
Aβ toxicity in neuronal cells [64]. Fe bound to Aβ also
accelerates ROS formation [65]. Thus, therapies that mod-
ulate Fe homeostasis in the AD brain have been proposed as
a means of reducing Aβ-associated Fe toxicity and reducing
APP translation and Aβ production [20, 66, 67]. This may
be a chicken-or-egg question: does Fe accumulation, exa-
cerbated by perturbation of miR-346-dependent regulation
of APP, lead to AD, or does it merely exacerbate symptoms
after the disease already exists?
In addition to Fe, several other metals play some role in the
production of APP and Aβ. These include lead (Pb) [39],
copper (Cu) [68–70], and manganese (Mn) [71, 72, 87]. Their
contributions are complex and often not overlapping. Cu, in
particular, appears to regulate transcription and translation
[69]. However, it may be a complex relationship. Although
Cu supplementation stimulated APP 5′-UTR activity [70], net
effects may vary by tissue [68–70]. It is noteworthy that Cu
binds IRP1 and reduces its ability to bind mRNA, although at
less efficiency than Fe [73]. Pb enhances IRP1 inhibition of
APP translation via enhancing IRP1:APP 5′-UTR interaction
[39]. Shorter-term exposures to Pb also increases IRP1 levels
before resulting in lower levels with more extended exposure.
This operates through Pb disruption of extracellular signal-
regulated kinase 1/2 [74]. A neurotoxic effect has also
recently been explicitly measured for Mn, via suppression of
APP 5′-UTR activity [87].
Fig. 7 FeAR nexus model of miR-346 participation in Fe homeostasis
and AD risk. Schematic illustrates interaction of miR-346 and IRP1 at
“FeAR nexus” in APP 5′-UTR. a Structure of the APP 5′-UTR
illustrating a putative hairpin loop [13, 15, 19] that includes both the
IRP1 site and miR-346 recognition sequence. b During Fe influx, IRP1
is recruited away from the APP 5′-UTR, no longer inhibiting APP
translation. Although this may “free” the APP 5′-UTR to bind with
miR-346/RISC (RISC represented by Ago2), the apparent stimulative
activity is parsimonously explained by disinhibition vs. IRP1. When
IRP1 is not inhibiting, binding by RISC offers no additional stimu-
lative effect. Cu also has some activity in recruiting IRP1 away from
the APP 5'-UTR. Cu has a lower affinity for IRP1 but is still able to
bind and partially recruit it away. c If Fe levels are low, IRP1 is not
recruited away and binds the APP 5′-UTR, inhibiting APP translation.
In addition, Mn may bind to IRP1 and prevent its recruitment by Fe or
otherwise interfere in Fe recruitment. Pb activates ERK1/2, which has
a complex cascade of consequences, some of which include complex
disruption of IRP1 levels. d Binding of the miR-346/RISC complex
would then disinhibit by displacing IRP1. Alternation of IRP1 inhi-
bition and miR-346/RISC disinhibition would facilitate APP
homeostasis
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In our studies, miR-346 upregulated Aβ in
U373 human astrocytoma cells but did not have a sig-
nificant effect on Aβ levels in primary human cell cul-
tures. In AD brain samples, miR-346 was significantly
downregulated in late-Braak stages. We had previously
reported that both miR-101 and miR-153 were also
downregulated in late-Braak AD, accompanied by sig-
nificant elevation of Aβ and APP [21, 22]. If miR-346 is
to upregulate APP, why would it be deficient in AD
brain? We admit that late-stage reduction in miRNA
species, without early-stage or prodromal evidence,
could reflect a general breakdown in miRNA regulation
that cuts across specific functions or be an epiphenomal
change reflecting broad changes in the relative number of
different cell types as neurodegeneration progresses. If
dysregulation of APP’s contribution to Fe homeostasis
plays a role in AD, that role would be in earlier stages of
the disorder, such as mild cognitive impairment (MCI)
and Braak stage I, and may not be reflected in the
“accumulative phase” (Braak II+).
We propose a “first-order” model that incorporates Fe
and miR-346, along with “supporting roles” played by Cu
and Mn (Fig. 7). Although Zn can bind IRP1 [88], and it
blocks APP ferroxidase activity it does not alter APP levels
[12]. Under our model, “healthy FeAR” is homeostatic. The
IRE and miR-346 sites partially overlap in the APP 5′-UTR
(Fig. 7a). Fe influx recruits IRP1 away from the APP 5′-
UTR, which may “free” the site, and is equivalent to simple
disinhibition (Fig. 7b). When Fe is reduced, IRP1 becomes
available and binds its site, inhibiting APP translation
(Fig. 7c). Binding of miR-346/RISC would displace IRP1,
disinhibiting APP translation in the same fashion that Fe
recruitment of IRP1 would (Fig. 7d). This process would
alternate back and forth between inhibition and disinhibi-
tion, permitting sufficient APP to be translated for its
multiple functions [75–78]. Notably, this phenomenon
would require the interaction of IRP1 with the 5'-UTR IRE
and, therefore, would be expected to be blunted in a setting
of “iron excess”, thereby providing a plausible hypothesis
for why the stimulatory effect was observed in human pri-
mary neuronal enriched cultures only after iron chela-
tion. Further experimental work will be necessary to better
integrate Cu, Mn, Pb, and IL-1 into the Fe-miR-346 activity
network. Considering clinical complications, unmodified
iron chelation therapy in AD is likely to be a poor treatment
strategy. Metal-complexing agents exist with more targeted
and less-systemic effects on metal ion binding and redis-
tribution, the so-called metal-protein attenuating com-
pounds [79, 80]. “XH1” binds Aβ and chelates metals. It
reduces APP protein expression in neuronal cells [81].
However, idiopathic anemia is a common comorbidity with
AD [82], and low hemoglobin associates with greater risk of
death among AD patients [83]. On the other hand, in a
Japanese study confined solely to dementia patients, sub-
jects had a direct association between greater levels of cir-
culating hemoglobin and brain accumulation of Aβ [84].
In the context of translational implications, we
observed that miR-346 levels are reduced in later stages of
AD, but we cannot necessarily infer from this that pro-
dromal AD or earlier stages of development are necessa-
rily due to deficiency of miR-346. Several cases of
reduced miRNAs have been found in association with AD
staging, in particular, we have reported that miR-101 and
miR-153, both of which downregulate APP expression,
are likewise reduced in AD [21, 22]. This may reflect
underlying etiology, or it may reflect general neurode-
generation and glial invasion. If these miRNAs are critical
to normal brain function, and they are likewise specifi-
cally expressed in neuronal cells, their loss in brain
samples may just as well reflect a change in proportion of
neuronal vs. non-neuronal cells in diseased brains.
Finally, we wish to make note of possible roles for Fe
deficiency in another pervasive brain disorder, schizo-
phrenia. Hippocampal Fe deficiency, both with and
without systemic anemia, resulted in impaired prepulse
inhibition (PPI) of the acoustic startle reflex. Impaired PPI
is a reliable measure of the schizophrenia endophenotype
of defective sensorimotor gating [85]. While no APP-Fe-
Schizophrenia axis has been found, that APP activity
includes significant regulation of Fe homeostasis suggests
that the miR-346/IRP-1/Fe pathway may function in other
neurological disorders.
From an AD etiology standpoint, Fe influx could be part
of a cascade of cellular stresses (e.g., redox stress and
inflammation) that would initially upregulate miR-346 and,
thereby, APP. In healthy conditions, this would eventually
result in negative feedback that reduces miR-346 and APP
to pre-stress levels. Under pathogenic conditions, negative
feedback to miR-346 might be insufficient to halt an APP
pathogenic cascade. Other mechanisms would drive excess
APP and Aβ, but miR-346 would have “fallen by the
wayside”, downregulated as a result of late AD neurobiol-
ogy. Only further experimental investigation could accu-
rately define the relationships. For example, our future work
would consider stimulation of the FeAR nexus by IL-1 [62],
and show direct evidence of IRP1-miR-346 competition or
how metallic ions other than Fe, such as Cu or Mn, could
alter the system. In addition, our future work would use the
full UTR sequence, which could add another layer of
complexity. It is noteworthy that the 5′-UTR for APP is also
transcriptionally active, as we have previously shown [37].
This includes a “CAGA box” that takes part in transforming
growth factor β activity in regulating APP transcription
[86]. It might be overly simplistic to presume that tran-
scriptional regulation directly interacts with translational
regulation merely because both stages happen to have
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overlapping target regions on the DNA and corresponding
RNA sequences. Nevertheless, the presence of such an
overlap could open up opportunities for drug modulation
that could target both stages through one site.
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